Related Experiment Video
Updated: Jun 21, 2026
06:11
Therapy Testing in a Spheroid-based 3D Cell Culture Model for Head and Neck Squamous Cell Carcinoma
Published on: April 20, 2018
Head and neck squamous cell carcinoma targeted chemosensitization.
Mindy R Figures1, Jessie Wobb, Koji Araki
1Department of Otorhinolaryngology-Head & Neck Surgery, University of Pennsylvania School of Medicine, Philadelphia, PA 19104, USA.
Summary
Fibroblast growth factor 2-targeted adenovirus-mediated mutant-Rad50 (FGF2-Ad-Rad50) gene therapy combined with cisplatin shows improved head and neck cancer treatment. This novel approach enhances anti-tumor effects by targeting DNA repair and tumor angiogenesis.
Area of Science:
- Oncology
- Gene Therapy
- Cancer Research
Background:
- Advanced head and neck squamous cell carcinoma (HNSCC) has poor treatment outcomes.
- Current therapies often result in significant chemotoxicity.
- Novel therapeutic strategies are needed to improve HNSCC treatment efficacy.
Purpose of the Study:
- To investigate the efficacy of fibroblast growth factor 2-targeted adenovirus-mediated mutant-Rad50 (FGF2-Ad-Rad50) gene transfer.
- To evaluate its role in enhancing chemosensitization for HNSCC.
- To assess its potential in reducing chemotoxicity.
Main Methods:
- A randomized controlled laboratory study using human HNSCC cells and a mouse model.
- FGF2-fab' molecule conjugated with an adenoviral mutant-Rad50 construct.
- In vitro and in vivo evaluation of FGF2-Ad-Rad50 combined with cisplatin treatment for tumor cytotoxicity, growth inhibition, and anti-tumor mechanisms.
Main Results:
- FGF2-targeted gene transfer significantly enhanced transgene expression in HNSCC cells compared to non-targeted methods.
- Combined FGF2-Ad-Rad50 and cisplatin demonstrated superior tumor suppression and increased DNA double-strand breaks.
- The combination therapy also exhibited anti-angiogenic properties.
Conclusions:
- The combination of FGF2-Ad-Rad50 and cisplatin significantly enhances anti-tumor effects in HNSCC.
- This strategy effectively targets DNA repair systems and tumor angiogenesis.
- The promising results support further clinical trials for HNSCC treatment.
More Related Videos
Related Concept Videos
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
01:28Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy. SP binds and activates these...
01:27Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists
5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...
02:50Combination Therapies and Personalized Medicine
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
01:29Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists
Dopamine receptor antagonists, also known as antipsychotic agents, are critical in managing chemotherapy-induced vomiting. These antiemetic agents block dopamine receptors in the chemoreceptor trigger zone (CTZ), inhibiting signal transmission to the vomiting center. Antipsychotic agents encompass phenothiazines (PTZ), butyrophenones, benzamides, and thienobenzodiazepines (Zyprexa), which are utilized for their antiemetic and sedative properties.
Phenothiazines, such as prochlorperazine...
Phenothiazines, such as prochlorperazine...